Skip to main content

Belite Bio, Inc

BLTE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001889109

In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.

Holders of 5% or more of BLTE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Belite Bio, Inc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BLTE
HolderLatest formStakeChangeFirst filedLatest filingFiling
Lin Bioscience International Ltd.13G53.70%17.1M sharesNewJan 21, 20251 filingJan 21, 2025SEC
Darwin Global Management, Ltd.13G/A8.10%3.03M shares+1.10 ppfrom 7.00%Dec 10, 20252 filingsFeb 17, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Belite Bio, Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BLTE
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 14, 20264:00 PM ETLin Yu-Hsin13G/A3.10%1.25M shares−4.00 ppfrom 7.10%Below 5%Mar 31, 2026SEC
Feb 17, 20264:30 PM ETDarwin Global Management, Ltd.and 2 others13G/A8.10%3.03M shares+1.10 ppfrom 7.00%Dec 31, 2025SEC
Dec 10, 20254:30 PM ETDarwin Global Management, Ltd.and 2 others13G7.00%2.62M sharesNewDec 3, 2025SEC
Jan 21, 20256:02 AM ETLin Yu-Hsin13G7.10%2.29M sharesNewDec 31, 2024SEC
Jan 21, 20256:01 AM ETLin Bioscience International Ltd.13G53.70%17.1M sharesNewDec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Belite Bio, Inc shares.

No Form 144 notices for Belite Bio, Inc are on file.